{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:04:19Z","timestamp":1793657059827,"version":"4.5.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM133504"],"award-info":[{"award-number":["GM133504"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005270","name":"McKnight Foundation","doi-asserted-by":"publisher","award":["McKnight Foundation Scholars Award"],"award-info":[{"award-number":["McKnight Foundation Scholars Award"]}],"id":[{"id":"10.13039\/100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012643","name":"Edward Mallinckrodt, Jr. Foundation","doi-asserted-by":"publisher","award":["Edward Mallinckrodt, Jr. Foundation Grant"],"award-info":[{"award-number":["Edward Mallinckrodt, Jr. Foundation Grant"]}],"id":[{"id":"10.13039\/100012643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011331","name":"Monique Weill-Caulier Trust","doi-asserted-by":"publisher","award":["Irma T. Hirschl\/Monique Weill-Caulier Trust Research Award"],"award-info":[{"award-number":["Irma T. Hirschl\/Monique Weill-Caulier Trust Research Award"]}],"id":[{"id":"10.13039\/100011331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The human trace amine-associated receptor 1 (hTAAR1, hTA1) is a key regulator of monoaminergic neurotransmission and the actions of psychostimulants. Despite preclinical research demonstrating its tractability as a drug target, its molecular mechanisms of activation remain unclear. Moreover, poorly understood pharmacological differences between rodent and human TA1 complicate the translation of findings from preclinical disease models into novel pharmacotherapies. To elucidate hTA1\u2019s mechanisms on the molecular scale and investigate the underpinnings of its divergent pharmacology from rodent orthologs, we herein report the structure of the human TA1 receptor in complex with a G\u03b1s heterotrimer. Our structure reveals shared structural elements with other TAARs, as well as with its closest monoaminergic orthologue, the serotonin receptor 5-HT4R. We further find that a single mutation dramatically shifts the selectivity of hTA1 towards that of its rodent orthologues, and report on the effects of substituting residues to those found in serotonin and dopamine receptors. Strikingly, we also discover that the atypical antipsychotic medication and pan-monoaminergic antagonist asenapine potently and efficaciously activates hTA1. Together our studies provide detailed insight into hTA1 structure and function, contrast its molecular pharmacology with that of related receptors, and uncover off-target activities of monoaminergic drugs at hTA1.<\/jats:p>","DOI":"10.1038\/s41467-023-44601-4","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T09:03:06Z","timestamp":1704186186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Molecular basis of human trace amine-associated receptor 1 activation"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-508X","authenticated-orcid":false,"given":"Gregory","family":"Zilberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5837-4518","authenticated-orcid":false,"given":"Alexandra K.","family":"Parpounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-8648","authenticated-orcid":false,"given":"Audrey L.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7616-1976","authenticated-orcid":false,"given":"Shifan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-7230","authenticated-orcid":false,"given":"Daniel","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"44601_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fphar.2017.00987","volume":"8","author":"G Rutigliano","year":"2017","unstructured":"Rutigliano, G., Accorroni, A. & Zucchi, R. The case for TAAR1 as a modulator of central nervous system function. Front Pharm. 8, 987 (2017).","journal-title":"Front Pharm."},{"key":"44601_CR2","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1073\/pnas.151105198","volume":"98","author":"B Borowsky","year":"2001","unstructured":"Borowsky, B. et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc. Natl Acad. Sci. USA 98, 8966\u20138971 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"44601_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"JR Bunzow","year":"2001","unstructured":"Bunzow, J. R. et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol. Pharm. 60, 1181\u20131188 (2001).","journal-title":"Mol. Pharm."},{"key":"44601_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bcp.2009.05.031","volume":"78","author":"Z Xie","year":"2009","unstructured":"Xie, Z. & Miller, G. M. Trace amine-associated receptor 1 as a monoaminergic modulator in brain. Biochem. Pharm. 78, 1095\u20131104 (2009).","journal-title":"Biochem. Pharm."},{"key":"44601_CR5","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1073\/pnas.0906522106","volume":"106","author":"A Bradaia","year":"2009","unstructured":"Bradaia, A. et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc. Natl Acad. Sci. USA 106, 20081\u201320086 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"44601_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41380-019-0469-2","volume":"26","author":"SM Underhill","year":"2021","unstructured":"Underhill, S. M. et al. Amphetamines signal through intracellular TAAR1 receptors coupled to Galpha(13) and Galpha(S) in discrete subcellular domains. Mol. Psychiatry 26, 1208\u20131223 (2021).","journal-title":"Mol. Psychiatry"},{"key":"44601_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","volume":"18","author":"FG Revel","year":"2013","unstructured":"Revel, F. G. et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol. Psychiatry 18, 543\u2013556 (2013).","journal-title":"Mol. Psychiatry"},{"key":"44601_CR8","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/adb.12410","volume":"22","author":"Y Pei","year":"2017","unstructured":"Pei, Y., Asif-Malik, A., Hoener, M. & Canales, J. J. A partial trace amine-associated receptor 1 agonist exhibits properties consistent with a methamphetamine substitution treatment. Addict. Biol. 22, 1246\u20131256 (2017).","journal-title":"Addict. Biol."},{"key":"44601_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry, M. D., Gainetdinov, R. R., Hoener, M. C. & Shahid, M. Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. Pharm. Ther. 180, 161\u2013180 (2017).","journal-title":"Pharm. Ther."},{"key":"44601_CR10","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","volume":"72","author":"FG Revel","year":"2012","unstructured":"Revel, F. G. et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol. Psychiatry 72, 934\u2013942 (2012).","journal-title":"Biol. Psychiatry"},{"key":"44601_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/jpet.114.220194","volume":"352","author":"S Fowler","year":"2015","unstructured":"Fowler, S. et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. J. Pharm. Exp. Ther. 352, 358\u2013367 (2015).","journal-title":"J. Pharm. Exp. Ther."},{"key":"44601_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1124\/jpet.115.229765","volume":"357","author":"LD Simmler","year":"2016","unstructured":"Simmler, L. D., Buchy, D., Chaboz, S., Hoener, M. C. & Liechti, M. E. In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J. Pharm. Exp. Ther. 357, 134\u2013144 (2016).","journal-title":"J. Pharm. Exp. Ther."},{"key":"44601_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic, N. et al. SEP-363856, a novel psychotropic agent with a unique, non-d(2) receptor mechanism of action. J. Pharm. Exp. Ther. 371, 1\u201314 (2019).","journal-title":"J. Pharm. Exp. Ther."},{"key":"44601_CR14","doi-asserted-by":"publisher","first-page":"e200175","DOI":"10.1212\/CPJ.0000000000200175","volume":"13","author":"SH Isaacson","year":"2023","unstructured":"Isaacson, S. H. et al. Ulotaront, a trace amine-associated receptor 1\/serotonin 5-ht(1a) agonist, in patients with parkinson disease psychosis: a pilot study. Neurol. Clin. Pr. 13, e200175 (2023).","journal-title":"Neurol. Clin. Pr."},{"key":"44601_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/13543784.2023.2206559","volume":"32","author":"GH Le","year":"2023","unstructured":"Le, G. H. et al. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials. Expert Opin. Investig. Drugs 32, 401\u2013415 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"44601_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","volume":"7","author":"CU Correll","year":"2021","unstructured":"Correll, C. U. et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 7, 63 (2021).","journal-title":"NPJ Schizophr."},{"key":"44601_CR17","unstructured":"A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia, https:\/\/classic.clinicaltrials.gov\/show\/NCT04072354."},{"key":"44601_CR18","unstructured":"A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia, https:\/\/classic.clinicaltrials.gov\/show\/NCT04092686."},{"key":"44601_CR19","unstructured":"A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder, https:\/\/classic.clinicaltrials.gov\/show\/NCT05729373."},{"key":"44601_CR20","unstructured":"A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder, https:\/\/classic.clinicaltrials.gov\/show\/NCT05593029."},{"key":"44601_CR21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1126\/science.1232807","volume":"340","author":"C Wang","year":"2013","unstructured":"Wang, C. et al. Structural basis for molecular recognition at serotonin receptors. Science 340, 610\u2013614 (2013).","journal-title":"Science"},{"key":"44601_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jmb.2007.12.028","volume":"376","author":"CB Roth","year":"2008","unstructured":"Roth, C. B., Hanson, M. A. & Stevens, R. C. Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure. J. Mol. Biol. 376, 1305\u20131319 (2008).","journal-title":"J. Mol. Biol."},{"key":"44601_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","volume":"25","author":"JA Ballesteros","year":"1995","unstructured":"Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366\u2013428 (1995).","journal-title":"Methods Neurosci."},{"key":"44601_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cell.2017.12.011","volume":"172","author":"T Che","year":"2018","unstructured":"Che, T. et al. Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell 172, 55\u201367.e15 (2018).","journal-title":"Cell"},{"key":"44601_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1124\/mol.108.048884","volume":"74","author":"LS Barak","year":"2008","unstructured":"Barak, L. S. et al. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol. Pharm. 74, 585\u2013594 (2008).","journal-title":"Mol. Pharm."},{"key":"44601_CR26","doi-asserted-by":"publisher","first-page":"21080","DOI":"10.1074\/jbc.M201330200","volume":"277","author":"CH Berlot","year":"2002","unstructured":"Berlot, C. H. A highly effective dominant negative alpha s construct containing mutations that affect distinct functions inhibits multiple Gs-coupled receptor signaling pathways. J. Biol. Chem. 277, 21080\u201321085 (2002).","journal-title":"J. Biol. Chem."},{"key":"44601_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen, S. G. et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477, 549\u2013555 (2011).","journal-title":"Nature"},{"key":"44601_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41586-023-06106-4","volume":"618","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. Structural basis of amine odorant perception by a mammal olfactory receptor. Nature 618, 193\u2013200 (2023).","journal-title":"Nature"},{"key":"44601_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature11896","volume":"494","author":"AJ Venkatakrishnan","year":"2013","unstructured":"Venkatakrishnan, A. J. et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185\u2013194 (2013).","journal-title":"Nature"},{"key":"44601_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/pr.114.009944","volume":"67","author":"M Michino","year":"2015","unstructured":"Michino, M. et al. What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Pharm. Rev. 67, 198\u2013213 (2015).","journal-title":"Pharm. Rev."},{"key":"44601_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41380-021-01250-7","volume":"27","author":"PC Nair","year":"2022","unstructured":"Nair, P. C. et al. Binding of SEP-363856 within TAAR1 and the 5HT(1A) receptor: implications for the design of novel antipsychotic drugs. Mol. Psychiatry 27, 88\u201394 (2022).","journal-title":"Mol. Psychiatry"},{"key":"44601_CR32","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.bmcl.2010.12.075","volume":"21","author":"H Stalder","year":"2011","unstructured":"Stalder, H., Hoener, M. C. & Norcross, R. D. Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773). Bioorg. Med. Chem. Lett. 21, 1227\u20131231 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"44601_CR33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1021\/acschemneuro.2c00086","volume":"13","author":"AM Decker","year":"2022","unstructured":"Decker, A. M. et al. Identification of a potent human trace amine-associated receptor 1 antagonist. ACS Chem. Neurosci. 13, 1082\u20131095 (2022).","journal-title":"ACS Chem. Neurosci."},{"key":"44601_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.106.112532","volume":"320","author":"DB Wainscott","year":"2007","unstructured":"Wainscott, D. B. et al. Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. J. Pharm. Exp. Ther. 320, 475\u2013485 (2007).","journal-title":"J. Pharm. Exp. Ther."},{"key":"44601_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S","volume":"37","author":"AM van Rhee","year":"1996","unstructured":"van Rhee, A. M. & Jacobson, K. A. Molecular architecture of g protein-coupled receptors. Drug Dev. Res. 37, 1\u201338 (1996).","journal-title":"Drug Dev. Res"},{"key":"44601_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/cb800304d","volume":"4","author":"ES Tan","year":"2009","unstructured":"Tan, E. S. et al. The molecular basis of species-specific ligand activation of trace amine-associated receptor 1 (TAAR(1)). ACS Chem. Biol. 4, 209\u2013220 (2009).","journal-title":"ACS Chem. Biol."},{"key":"44601_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1124\/jpet.109.164962","volume":"333","author":"DF Cummings","year":"2010","unstructured":"Cummings, D. F., Ericksen, S. S., Goetz, A. & Schetz, J. A. Transmembrane segment five serines of the D4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548. J. Pharm. Exp. Ther. 333, 682\u2013695 (2010).","journal-title":"J. Pharm. Exp. Ther."},{"key":"44601_CR38","doi-asserted-by":"publisher","first-page":"37779","DOI":"10.1074\/jbc.M002092200","volume":"275","author":"G Liapakis","year":"2000","unstructured":"Liapakis, G. et al. The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J. Biol. Chem. 275, 37779\u201337788 (2000).","journal-title":"J. Biol. Chem."},{"key":"44601_CR39","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim, K. et al. Structure of a hallucinogen-activated gq-coupled 5-ht2a serotonin receptor. Cell 182, 1574\u20131588.e1519 (2020).","journal-title":"Cell"},{"key":"44601_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","volume":"168","author":"D Wacker","year":"2017","unstructured":"Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377\u2013389.e312 (2017).","journal-title":"Cell"},{"key":"44601_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nchembio.2527","volume":"14","author":"JD McCorvy","year":"2018","unstructured":"McCorvy, J. D. et al. Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs. Nat. Chem. Biol. 14, 126\u2013134 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"44601_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00441-020-03331-5","volume":"383","author":"A Dewan","year":"2021","unstructured":"Dewan, A. Olfactory signaling via trace amine-associated receptors. Cell Tissue Res. 383, 395\u2013407 (2021).","journal-title":"Cell Tissue Res"},{"key":"44601_CR43","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1021\/cb300111e","volume":"7","author":"DM Ferrero","year":"2012","unstructured":"Ferrero, D. M. et al. Agonists for 13 trace amine-associated receptors provide insight into the molecular basis of odor selectivity. ACS Chem. Biol. 7, 1184\u20131189 (2012).","journal-title":"ACS Chem. Biol."},{"key":"44601_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nature05066","volume":"442","author":"SD Liberles","year":"2006","unstructured":"Liberles, S. D. & Buck, L. B. A second class of chemosensory receptors in the olfactory epithelium. Nature 442, 645\u2013650 (2006).","journal-title":"Nature"},{"key":"44601_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2007.06.007","volume":"116","author":"DK Grandy","year":"2007","unstructured":"Grandy, D. K. Trace amine-associated receptor 1-Family archetype or iconoclast? Pharm. Ther. 116, 355\u2013390 (2007).","journal-title":"Pharm. Ther."},{"key":"44601_CR46","doi-asserted-by":"publisher","first-page":"D335","DOI":"10.1093\/nar\/gkaa1080","volume":"49","author":"AJ Kooistra","year":"2021","unstructured":"Kooistra, A. J. et al. GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 49, D335\u2013D343 (2021).","journal-title":"Nucleic Acids Res"},{"key":"44601_CR47","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1016\/j.molcel.2022.05.031","volume":"82","author":"S Huang","year":"2022","unstructured":"Huang, S. et al. GPCRs steer G(i) and G(s) selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors. Mol. Cell 82, 2681\u20132695.e2686 (2022).","journal-title":"Mol. Cell"},{"key":"44601_CR48","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1021\/acsmedchemlett.1c00527","volume":"13","author":"MLR Heffernan","year":"2022","unstructured":"Heffernan, M. L. R. et al. Ulotaront: a TAAR1 agonist for the treatment of schizophrenia. ACS Med. Chem. Lett. 13, 92\u201398 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"44601_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","volume":"150","author":"JD McCorvy","year":"2015","unstructured":"McCorvy, J. D. & Roth, B. L. Structure and function of serotonin G protein-coupled receptors. Pharm. Ther. 150, 129\u2013142 (2015).","journal-title":"Pharm. Ther."},{"key":"44601_CR50","doi-asserted-by":"publisher","first-page":"11443","DOI":"10.1021\/ja105108q","volume":"132","author":"D Wacker","year":"2010","unstructured":"Wacker, D. et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 132, 11443\u201311445 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"44601_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid, M., Walker, G. B., Zorn, S. H. & Wong, E. H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 23, 65\u201373 (2009).","journal-title":"J. Psychopharmacol."},{"key":"44601_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.euroneuro.2008.11.001","volume":"19","author":"R Ghanbari","year":"2009","unstructured":"Ghanbari, R., El Mansari, M., Shahid, M. & Blier, P. Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur. Neuropsychopharmacol. 19, 177\u2013187 (2009).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"44601_CR53","doi-asserted-by":"publisher","first-page":"eabo4158","DOI":"10.1126\/sciadv.abo4158","volume":"8","author":"X Teng","year":"2022","unstructured":"Teng, X. et al. Structural insights into G protein activation by D1 dopamine receptor. Sci. Adv. 8, eabo4158 (2022).","journal-title":"Sci. Adv."},{"key":"44601_CR54","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cell.2021.01.028","volume":"184","author":"P Xiao","year":"2021","unstructured":"Xiao, P. et al. Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes. Cell 184, 943\u2013956.e918 (2021).","journal-title":"Cell"},{"key":"44601_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/360161a0","volume":"360","author":"D Oksenberg","year":"1992","unstructured":"Oksenberg, D. et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360, 161\u2013163 (1992).","journal-title":"Nature"},{"key":"44601_CR56","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/pr.118.015552","volume":"73","author":"NM Barnes","year":"2021","unstructured":"Barnes, N. M. et al. International union of basic and clinical pharmacology. cx. classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharm. Rev. 73, 310\u2013520 (2021).","journal-title":"Pharm. Rev."},{"key":"44601_CR57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353\u2013359 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"44601_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1586\/ern.10.49","volume":"10","author":"RS McIntyre","year":"2010","unstructured":"McIntyre, R. S. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. Expert Rev. Neurother. 10, 645\u2013649 (2010).","journal-title":"Expert Rev. Neurother."},{"key":"44601_CR59","unstructured":"Chalecka-Franaszek, E. Asenapine: Pharmacology\/toxicology review and evaluation. Food and Drug Administration Center for Drug Evaluation and Research (2009)."},{"key":"44601_CR60","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"44601_CR61","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"44601_CR62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"44601_CR63","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D. Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"44601_CR64","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1107\/S2059798319011471","volume":"75","author":"D Liebschner","year":"2019","unstructured":"Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D. Struct. Biol. 75, 861\u2013877 (2019).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"44601_CR65","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1107\/S2059798321009475","volume":"77","author":"K Yamashita","year":"2021","unstructured":"Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallogr D. Struct. Biol. 77, 1282\u20131291 (2021).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"44601_CR66","unstructured":"The PyMOL Molecular Graphics System, Version 2.0 (Schr\u00f6dinger, LLC)."},{"key":"44601_CR67","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1126\/science.1232808","volume":"340","author":"D Wacker","year":"2013","unstructured":"Wacker, D. et al. Structural features for functional selectivity at serotonin receptors. Science 340, 615\u2013619 (2013).","journal-title":"Science"},{"key":"44601_CR68","doi-asserted-by":"publisher","first-page":"D1503","DOI":"10.1093\/nar\/gkac1062","volume":"51","author":"A Iudin","year":"2023","unstructured":"Iudin, A. et al. EMPIAR: the electron microscopy public image archive. Nucleic Acids Res. 51, D1503\u2013D1511 (2023).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44601-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44601-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44601-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T13:04:06Z","timestamp":1704459846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-44601-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44601"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-44601-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.09.06.556555","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"21 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}